Clinical Trial Search

Phase 3 N=3,630 Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Primary: The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination — 1.21; 1.19; 1.19; 87 Titers

Novartis Vaccines Results Apr 2015 8.0% serious AE View details

Phase 3 N=185 A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate

Rheumatoid Arthritis

Primary: Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24 — 0.13; 0.39; 1.33 Units on a scale

Hoffmann-La Roche Results Apr 2015 4.7% serious AE View details

Phase 3 N=508 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Primary: Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination. — 7.38; 8.3; 6.5; 68 Titers

Novartis Vaccines Results Apr 2015 4.6% serious AE View details

Phase 3 N=1,116 Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Influenza

Primary: Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1…

Pfizer Results Apr 2015 1.1% serious AE View details

Phase 3 N=1,088 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Primary: Overall Survival — 34.66; 30.29 Months

Janssen Research & Development, LLC Results Apr 2015 35.0% serious AE View details

Phase 3 N=189 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

Peyronie's Disease

Primary: Percentage Change From Baseline in Penile Curvature — -36.3 percentage of curvature change

Endo Pharmaceuticals Results Apr 2015 1.6% serious AE View details

Phase 3 N=417 Study of AA4500 in the Treatment of Peyronie's Disease

Peyronie's Disease

Primary: Percentage Change From Baseline in Penile Curvature — -37.6; -21.3 percentage of curvature change — p=0.0005

Endo Pharmaceuticals Results Apr 2015 8.2% serious AE View details

Phase 3 N=218 Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

Chemotherapy Associated Neutropenia · Breast Cancer

Primary: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy — 1.17; 1.2 Days

Sandoz Results Apr 2015 6.5% serious AE View details

Phase 3 N=45 RELOVAIR® Lung Deflation Study

Pulmonary Disease, Chronic Obstructive

Primary: Mean Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVI) at the End of the Overall Treatment Period — -0.47; 5.35 Milliliter per meter square…

GlaxoSmithKline Results Apr 2015 0.0% serious AE View details

Phase 3 N=39 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem

Hypertrophic Cardiomyopathy

Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…

Brigham and Women's Hospital Results Apr 2015 0.0% serious AE View details

Phase 3 N=50 Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza · Influenza Vaccines

Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Overall and by Age Category (18-64 and >64 Years of Age). — 45; 1; 46; 4 Participants

GlaxoSmithKline Results Apr 2015 0.0% serious AE View details

Phase 3 N=110 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Polycythemia Vera

Primary: Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative…

Incyte Corporation Results Apr 2015 8.2% serious AE View details

Phase 3 N=415 Study of AA4500 in the Treatment of Peyronie's Disease

Peyronie's Disease

Primary: Percentage Change From Baseline in Penile Curvature — -30.5; -15.2 percentage of curvature change — p=.0059

Endo Pharmaceuticals Results Apr 2015 3.9% serious AE View details

Phase 3 N=38 A Study to Test the Use of Duloxetine for Pain in MS

Multiple Sclerosis

Primary: Percent Change in Worst Pain Score — -29.1; -11.5 percent reduction on 0-10 analog scale — p=0.016

Brown, Theodore R., M.D., MPH Results Apr 2015 0.0% serious AE View details

Phase 3 N=1,432 Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Hormone Refractory Prostate Cancer

Primary: Bone Metastasis-free Survival — 768.0; 897.00 days — p=0.0284

Amgen Results Apr 2015 45.8% serious AE View details